Establishment of an evaluation system for myocardial regeneration therapy using an in vitro myocardial model using hiPS cells

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K08842
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55030:Cardiovascular surgery-related
• Research Institution: Osaka University
• Principal Investigator: Takeda Maki 大阪大学, 大学院医学系研究科, 招へい教員 (70717446)
• Co-Investigator(Kenkyū-buntansha): 河村 拓史 大阪大学, 大学院医学系研究科, 助教 (60839398)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 心筋再生治療 / iPS細胞 / in vitroモデル

Outline of Final Research Achievements

In this study, we aimed to evaluate for the therapeutic response of myoblast sheet treatment using in vitro myocardial model.
Among patients with dilated cardiomyopathy who underwent myoblast cell sheet transplantation, we identified cases in which significant improvement (responder) or no improvement (non-responder) was observed after transplantation. We generated human induced pluripotent stem cells using myoblasts from these patients in each group and differentiated into cardiomyocytes. Cardiomyocytes in both groups showed pathological conditions like dilated cardiomyopathy, including cell hypertrophy, sarcomere abnormalities, and contractile abnormalities. When myoblast culture supernatant, which mimics myoblast cell sheet transplantation, was applied to cardiomyocytes in both groups, different trends were observed in both groups, suggesting the possibility of evaluating therapeutic response in vitro.

Free Research Field

幹細胞生物学

Academic Significance and Societal Importance of the Research Achievements

拡張型心筋症の発症には遺伝的要因や環境要因が複雑に関与しており、症状・治療応答性についても多岐にわたる。治療前のなんらかの患者背景が治療応答性に影響を及ぼしている可能性が考えられるが、関連性は明らかになっていない。治療応答性を事前に評価することができれば、より早期に最適な治療選択が可能となると考えられ、患者負担の減少、医療経済の抑制にも繋がるため、学術的・社会的意義は大きいと考える。